A RETROSPECTIVE ANALYSIS OF SEQUENTIAL USE OF THE TYROSINE KINASE INHIBITORS (TKI) SORAFENIB (SOR) AND SUNITINIB (SUN) IN METASTATIC RENAL CELL CARCINOMA (mRCC)

被引：0
|
作者：
Calvani, N. [1 ,2 ]
Chetri, M. C. [1 ,2 ]
Cinefra, M. [1 ,2 ]
D'Amico, M. [1 ,2 ]
Fedele, P. [1 ,2 ]
Marino, M. [1 ,2 ]
Mazzoni, E. [1 ,2 ]
Nacci, A. [1 ,2 ]
Orlando, L. [1 ,2 ]
Rizzo, P. [1 ,2 ]
Schiavone, P. [1 ,2 ]
Sponziello, F. [1 ,2 ]
Cinieri, S. [1 ,2 ]
机构：
[1] A Perrino Hosp, Div Med Oncol, Brindisi, Italy
[2] A Perrino Hosp, Breast Unit, Brindisi, Italy
来源：
CANCER TREATMENT REVIEWS | 2010年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
14
引用
收藏
页码：S99 / S99
页数：1
相关论文
共 50 条
  • [41] Tyrosine-kinase inhibitor sorafenib (S) in treatment of metastatic renal cell carcinoma cancer (mRCC) with lung metastases
    Popova, Irina L.
    Vladimirova, Liubov Yu
    Abramova, Natalya A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib
    Plantade, A.
    Choueiri, T.
    Escudier, B.
    Rini, B.
    Negrier, S.
    Ravaud, A.
    Oudard, S.
    Elson, P.
    Bukowski, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Retrospective evaluation of tyrosine kinase inhibitor (TKI)-everolimus (eve) and/or TKI-eve-TKI sequences in metastatic renal cell carcinoma (mRCC): A French survey-The sector study.
    Oudard, Stephane
    Joly, Florence
    Geoffrois, Lionnel
    Laguerre, Brigitte
    Houede, Nadine
    Barthelemy, Philippe
    Gross-Goupil, Marine
    Yann-Alexandre, Vano
    Lucidarme, Olivier
    Bidault, Francois
    Kelkouli, Nadia
    Escudier, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [44] Sequential therapy with sorafenib and sunitinib in metastasized renal cell carcinoma (mRCC): a retrospective multi-center study and meta-analysis of available trials
    Liewen, H.
    Castonay, R.
    Haile, S. R.
    Cathomas, R.
    Rothermund, C.
    Siciliano, R. D.
    Stoll, S.
    Knuth, A.
    Renner, C.
    Samaras, P.
    Stenner, F.
    ONKOLOGIE, 2011, 34 : 183 - 184
  • [45] Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients
    Sablin, M. P.
    Bouaita, L.
    Balleyguier, C.
    Gautier, J.
    Celier, C.
    Balcaceres, J. L.
    Oudard, S.
    Ravaud, A.
    Negrier, S.
    Escudier, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] Response of renal lesions in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib - a single center retrospective analysis
    Seidel, C.
    Fenner, M.
    Reuter, C.
    Ivanyi, P.
    Ganser, A.
    Gruenwald, V.
    EJC SUPPLEMENTS, 2009, 7 (02): : 438 - 438
  • [47] SEQUENTIAL TARGET THERAPY FOR METASTATIC RENAL CELL CARCINOMA: COMPARISON OF SUNITINIB+SORAFENIB VS. SORAFENIB+SUNITINIB
    Antonelli, Alessandro
    Daja, Julian
    Ferrari, Vittorio
    Arrighi, Nicola
    Cunico, Sergio Cosciani
    Simeone, Claudio
    ANTICANCER RESEARCH, 2011, 31 (05) : 1922 - 1923
  • [48] Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)
    Santini, D.
    Santoni, M.
    Conti, A.
    Procopio, G.
    Verzoni, E.
    Galli, L.
    Di Lorenzo, G.
    De Giorgi, U.
    De Lisi, D.
    Nicodemo, M.
    Maruzzo, M.
    Massari, F.
    Buti, S.
    Biasco, E.
    Ricotta, R.
    Porta, C.
    Vincenzi, B.
    Marchetti, P.
    Cascinu, S.
    Tonini, G.
    ANNALS OF ONCOLOGY, 2015, 26 : 57 - 57
  • [49] Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors
    Kumano, Masafumi
    Miyake, Hideaki
    Harada, Ken-ichi
    Fujisawa, Masato
    MEDICAL ONCOLOGY, 2013, 30 (04)
  • [50] Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors
    Masafumi Kumano
    Hideaki Miyake
    Ken-ichi Harada
    Masato Fujisawa
    Medical Oncology, 2013, 30
12345